Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
New Formulations for Cancer Therapy Volume II
share announcement

New Formulations for Cancer Therapy Volume II

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 1881

Special Issue Editors

Prof. Dr. Ana Isabel Torres-Suárez

E-Mail Website
Guest Editor
Department of Pharmaceutics and Food Technology, Complutense University of Madrid, 28040 Madrid, Spain
Interests: nanomedicine; drug delivery systems; cancer; drug targeting; brain tumors; cannabinoids; microparticles; nanocarriers
Special Issues, Collections and Topics in MDPI journals
Dr. Juan Aparicio-Blanco

E-Mail Website
Guest Editor
Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain
Interests: nanomedicine; brain drug delivery; brain diseases; lipid nanocapsules; glioma; cannabinoids; tailored carriers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The search for new formulations for cancer therapy to achieve improved bioavailability, efficacy, and safety constitutes the holy grail of anticancer drug research. In the fight against cancer, in recent years, researchers have put tremendous effort into evaluating the potential of drug carriers for this purpose. Noticeably, in the case of chemotherapeutic agents, drug encapsulation within carriers greatly contributes to reducing their frequent non-specific side effects that often lead to treatment discontinuation. Despite several carrier-based formulations achieving clinical translation, promising possibilities to develop second-generation formulations that address unmet advanced cancer-related medical challenges and ultimately enable the development of not only safer but also more efficacious drug delivery systems still remain. To this end, the harmonized integration of researchers from diverse multidisciplinary fields (namely, formulation scientists, cancer pathologists, clinical doctors) is required to foster the development of clinically translatable novel formulations for cancer therapy.

In this context, the aim of this Special Issue on “New Formulations for Cancer Therapy Volume II” is to gather papers addressing state-of-the-art trends and future directions in the development of clinically translatable carrier-based formulations for cancer treatment on topics ranging from rational design to relevant preclinical and/or clinical testing of efficacy, pharmacokinetics, and toxicity. Original research papers, communications and review articles are welcome.

Prof. Dr. Ana Isabel Torres-Suárez
Prof. Dr. Juan Aparicio-Blanco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine
  • cancer
  • anticancer drug delivery
  • implants
  • microcarriers
  • gene therapy
  • combination therapy
  • theranostics
  • targeted therapy
  • translational cancer nanomedicine

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 1409 KiB  
Article
The Chemo-Sensitizing Effect of Doxorubicin of Apple Extract-Enriched Triterpenic Complex on Human Colon Adenocarcinoma and Human Glioblastoma Cell Lines
by Aurita Braciuliene, Valdimaras Janulis and Vilma Petrikaite
Pharmaceutics 2022, 14(12), 2593; https://doi.org/10.3390/pharmaceutics14122593 - 24 Nov 2022
Cited by 2 | Viewed by 1232
Abstract
Cancer cells’ resistance to anticancer drugs represents a major clinical problem and the most important failure of treatment. Combination chemotherapy is more effective than monotherapy due to additive or synergistic effects. The aim of our research was to assess the effects of the [...] Read more.
Cancer cells’ resistance to anticancer drugs represents a major clinical problem and the most important failure of treatment. Combination chemotherapy is more effective than monotherapy due to additive or synergistic effects. The aim of our research was to assess the effects of the combinations of apple extract’s triterpenic compounds, individual triterpenic acids, and doxorubicin (DOX) on human colon adenocarcinoma (HT-29) and human glioblastoma (U-87) cell lines in 2D and 3D cultures. The effect of the combination of apple extracts, the triterpenic standards, and DOX against HT-29 and U-87 cell viability was tested by the MTT and spheroid growth assays. Cell line HT-29 was more sensitive to DOX when incubated with all tested apple extracts than DOX alone. Cell line HT-29 was the most strongly sensitive to DOX when it was treated with 5 µM oleanolic acid (change of EC50 = −64.6% ± 4.4%) and with 5 µM ursolic acid (change of EC50 = −61.9% ± 8.8%) in 2D culture. Meanwhile, cell line U-87 was the most strongly sensitive to DOX when treated with 2 µM betulinic acid (change of EC50 = −45.1% ± 4.5%) in 2D culture. The combination of apple extract (E3) and DOX reduced the viability of HT-29 spheroids the most (spheroid viability reduced from −19.9% to −10.9%, compared to spheroids treated with DOX alone). Our study in 2D and 3D cultures showed that combining apple extract’s triterpenic complexes or individual triterpenic acids with DOX may sensitize chemotherapeutic drugs and increase the cytotoxicity effects in HT-29 and U-87 cell lines. Full article
(This article belongs to the Special Issue New Formulations for Cancer Therapy Volume II)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop